Диссертация (1144999), страница 55
Текст из файла (страница 55)
– Vol. 285. – Р. 367-371.190. Krowka, MJ. Hepatopulmonary syndromes / MJ. Krowka// Gut. – 2000. – Vol.46, № 1. – Р. 1-4.191. Kunos, G. Endocannabinoids / G. Kunos // EASL monothematic conference:Portal hypertension: Advances in knowledge, evaluation and management Budapest,Hungary, January 22-24. – 2009. – P. 25.293192. Kwon, H.
Hepatitis B therapy / H. Kwon, AS. Lok// Nat.Rev. Gastroenterol.Hepetol. – 2011. - Vol. 8. – P. 275-284.193. Lack of vasopressin action on splanchnic hemodynamics during bleeding: a studyin conscious, portal hypertensive rats / D. Girod, SS. Lee, D. Valla [et al.]//Hepatology. – 1988. – Vol. 8, № 1. – Р.
10-15.194. Lavanchy, D. The global burden of hepatitis C/ D. Lavanchy // Liver Int. – 2009.– Vol. 29. – P. 74-81.195. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation ofresistance in the hepatic sinusoids / V. Shah, FG. Haddad, G. Garcia-Cardena [et al.]// J Clin Invest. – 1997. – Vol. 100. – Р. 2923-2930.196. Liver stiffness measurement is correlated with hepatic venous pressure gradient inpatients with uncomplicated alcoholic and HCV related cirrhosis / M.
Lemoine, S.Katsahian, P. Nahon [et al.] // Hepatology. – 2006. – Vol. 44 (Suppl. I). – P. 42.197. Long-term hemodynamic effects of ketanserin, a 5-hydrotrjptamine blocker, inportahypertenzie patients / J. Vorobioff, G. Garcia - Tsao, G. Aceves [et al.] // Hepatology. – 1989. - Vol. 9, № 1. – P 88-91.198. Malekzaden, R Обратимость цирроза печени при хроническом гепатите В / RMalekzaden // Клинич. гастроэнтерол. и гепатол. Русское издание.
– 2009. – Т. 2,№ . - С. 184-187.199. Marlin J. Портальная гипертензия при первичном билиарном циррозе: потенциально обратимое состояние, ведущее к летальному исходу / J. Marlin //Клинич. гастроэнтерол. и гепатол. русское издание. – 2009. – Т. 2, №3. – C. 211212.200. Mc Carthy, L.J., Danielson C.F., Rothenberger S.S. Indications for EmergencyApheresis Procedures / L.J. Mc Carthy, C.F. Danielson, S.S. Rothenberger // Crit.Rev.
Clin. Lab. Sciences. - 1997. - Vol. 34, № 6. - P. 573-610.201. Measurement of hepatic blood flow, hepatic extraction and intrinsic clearance ofindocyanine green in cirrhosis. Comparison of a non-invasive pharmacokinetic method with measurements using hepatic vein catheterization / M. Navasa, J. Bosch, R.Mastai [et al.] // Eur J Gastroenterol Hepatol.
– 1991. – Vol. 3. – P. 305-312.202. Miche,l T. Nitric oxide synthases: Which, where, how, and why / T. Michel, O.Feron // J Clin Invest. – 1997. – Vol. 100. – P. 2146-2152.203. Monitoring liver elasticity: a new toll to measure lever fibrosis during therapy / B.Coco, F. Oliveri, P. Colombatto [et al.] // Hepatology. – 2005. – Vol. 42 (suppl.1). –P. 606.204. Moreau, R. Lipid metabolism and vascular function in portal hypertension / R.Moreau // EASL monothematic conference: Portal hypertension: Advances inknowledge, evaluation and management Budapest, Hungary, January 22-24. 2009. –P.
26-27.205. MR angiography of the portal venous system: techniques, interpretation, and clinical applications / JR. Leyendecker, E. Rivera, WK. Washburn [et al.] // Radiographics. – 1997. – Vol. 17. – P. 1425-1443.206. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance294in the isolated and perfused rat liver / S. Fiorucci, E.
Antonelli, V. Brancaleone [etal.] // J. Hepatol.-2003. – Vol. 39, № 6. - P. 932-939.207. Non-invasive diagnosis of esophageal varices in chronic liver diseases / C.Pilette, F. Oberti, C. Aube [et al.] // J Hepatol. – 1999. – Vol. 31. – P. 867-873.208. Noninvasive estimation of liver fibrosis and response to interferon therapy by aserum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease /Y. Saitou, K. Shiraki, Y.
Yamanaka [et al.] // World J. Gastroenterol. – 2005. – Vol.11, № 4 – P. 476-481.209. Nаkаta, К., Suguirа М., Маkаtshuho Т. — "Aсtа haemat. jар.". – 1955. - Vol. 18.- P. 92.210. Observer variability in echo-Doppler measurements of portal flow in cirrhotic patients and normal volunteers / C. Sabba, GG. Weltin, DV. Cicchetti [et al.] // Gastroenterology. – 1990. – Vol. 98. – P. 1603-1611.211. Pichard, D.N.C. Clinical pharmacology of moxonidine / D.N.C. Pichard. - London: Roy. Soc. Med., 1996.
– P. 31-75.212. Pierre, M. H. Портальная гипертензия и первичный билиарный цирроз: эффект длительного лечения урсодезоксихолевой кислотой. / M.H. Pierre//Клинич. гастроэнтерол. и гепатол. Русское издание. – 2009. – Т. 2, № 3. – C.203-210.213. Pinzani, M. Angiogenesis and inflammation / M.
Pinzani // EASL monothematicconference: Portal hypertension: Advances in knowledge, evaluation and management Budapest, Hungary, January 22-24. – 2009. – P. 38.214. Pinzani, M. Cytokine receptors and signaling in hepatic stellate cells / M. Pinzani, F.Marra // Semin. Liver Dis. – 2001. – Vol. 21. – Р. 397-416.215. Pinzani, M. Fibrosis in chronic liver disease: diagnostic and management / M.Pinzani, K. Rombouts, S. Colagrande // J Hepatol.
– 2005. – Vol. 42. – Р. 12-36.216. Pirogova, I.J. Non-invasive diagnostics liver fibrosis and histologic activity index in patients with chrinic viral hepatitis at normal level АLT / I.J. Pirogova, M.V.Maevskaja, S.A. Pyshkin // Abstract of Prague Hepatology Meeting.- 2010.- P.107108.217. Placebo-controlled comparison of the efficacy and tolerability of onсe-dailymoxonidine and enalapril in mild–to–moderate essential hypertension / H.E.
Kuppers, B.A. Jager, J.H. Luszik [et al.] // J. Hypertension. – 1997. – Vol. 15. – Р. 93-97.218. Popper, H. Pathologic aspect of cirrhosis / H. Popper // Amer. J Path. – 1977. –Vol. 87, № 1. – Р. 228-264.219. Portal hypertension / J. Bosch, M. Navasa, JC. Garcia-Pagan [et al.] // Med. Clin.North Am 73.
– 1989. – P. 931-953.220. Portal hypertension and variceal bleeding: An AASLD single topic symposium /ND. Grace, RJ. Groszmann, G. Garcia-Tsao [et al.] // Hepatology. – 1998. – Vol. 28.– P. 868-880.221. Portographic opacification of hepatic veins - and (anomalous) anastomoses between the portal and hepatic veins in cirrhosis – indications of extensive intrahepaticshunts / K. Ohnishi, N. Chin, M.
Saito [et al.] // Am. J. Gastroenterol. – 1986. – Vol.81. – P. 975-978.295222. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta / S. Kanzler, M. Beumann, P. Schirmacher [et al.] // J. Viral Hepat. – 2001/ - Vol. 8, № 6.
– P. 430-437.223. Predictive value of the variceal pressure response to continued pharmacologicaltherapy in patients with cirrhosis and portal hypertension / A. Escorsell, JM. Bordas,B. Castaneda [et al.] // Hepatology. – 2000. – Vol. 31, № 5. – P. 1061-1067.224. Predictors of large esophageal varices in patients with cirrhosis / N.
Chalasani,TF. Imperiale, A. Ismail [et al.] // Am J Gastroenterol. – 1999. – Vol. 94. – Р. 32853291.225. Primignani, M., Sclerotherapy plus octreotide versus sclerotherapy alone in theprevention of early rebleeding from esophageal varices: a randomized, double-blind,placebo-controlled, multicenter trial./ M. Primignani , B. Andreoni , L. Carpinelli //Hepatology. – 1995.
– Vol. 21, № 5. – P. 1322-1327.226. Prognostic value of early measurements of portal pressure in acute variceal bleeding / E. Moitinho, A. Escorsell, JC. Bandi [et al.] // Gastroenterology. – 1999. – Vol.117. – P. 626-631.227. Pulmonary vascular disorders in portal hypertension / P. Herve, D. Lebrec, F.Brenot [et al.] // Eur Respir J. – 1998.
– Vol. 11. – Р. 1153-1166.228. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis / F. Feu, JC. Garcia-Pagan, J.Bosch [et al.] // Lancet. – 1995. – Vol. 346. – P. 1056-1059.229. Reproducibility of transient elastography (TE) in assessing hepatic fibrosis / M.Fraquelli, C. Rigamonti, D. Conte [et al.] // Hepatology. – 2006.
Vol. 44 (Suppl. 1). –P. 687.230. Rockey, DC. Activation-dependent contractility of rat hepatic lipocytes in cultureand in vivo / DC Rockey, CN Housset, SL Friedman // J Clin Invest. – 1993. – Vol.92. – Р. 1795-1804.231. Rockey, DC. Endothelin induced contractility of stellate cells from normal andcirrhotic rat liver: Implications for regulation of portal pressure and resistance / DCRockey, RA Weisiger // Hepatology.
– 1996. – Vol. 24. – Р. 233-240.232. Rockey, DC. Reduced nitric oxide production by endothelial cells in cirrhotic ratliver: Endothelial dysfunction in portal hypertension / DC Rockey, JJ Chung // Gastroenterology. – 1998. – Vol. 114. – Р. 344-351.233. Rodriguez, A. Garcia-Pagan Eicosanoids / A. Rodriguez, J.C. Vilarrupla // EASLmonothematic conference: Portal hypertension: Advances in knowledge, evaluationand management Budapest, Hungary, January 22-24. – 2009. – P. 19-22.234. Rupp, H.
Excess catechol-amines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target? / H. Rupp, Jacob R. //Medical Hypotheses. – 1995. – Vol. 44. – Р. 217-225.235. Rаррароrt, А. М. — "Мiсrоvasc. Rеs." / А. М. Rаррароrt. – 1973. - Vol. 6. – Р.212.236. Schaffer, F. Chronic hepatitis / F. Schaffer, F.M.
Klion // Annu. Rev. Med. –1968. - Vol. 19. – P. 25-38.296237. Serum markers detect the presence of liver fibrosis: a cohort study / W.M.C. Rosenberg, M. Voelker, R. Thiel [et al.]// Gastroenterology. – 2004. – Vol. 127. – P.1704-1713.238. Shah, V. Cellular and molecular basis of portal hypertension / V.Shah // Clin.,Liver Dis. – 2001. – Vol. 3. – P.
629-644.239. Shah, V. Hepatic NO in cirrhosis / V. Shah // EASL monothematic conference:Portal hypertension: Advances in knowledge, evaluation and management Budapest,Hungary, January 22-24. – 2009. – P. 18.240. Sorensen, T.I.A. Construction and validation of prognosis models / T.I.A.Sorensen // EASL monothematic conference: Portal hypertension: Advances inknowledge, evaluation and management Budapest, Hungary, January 22-24. – 2009.– P. 46.241. Tanikawa, K. Hepatic sinusoidal cell and circulation / K. Tanikawa //J.Gastroenterol. Hepatol. – 1995. – Vol. 10 (Suppl.1). – P. 8-11.242. Thabut, D. Evolution of fibrosis and portal hypertension: iv.
non-invasive assessment-french approfch / D. Thabut // EASL monothematic conference: Portal hypertension: Advances in knowledge, evaluation and management Budapest, Hungary,January 22-24. – 2009. – P. 46.243. The contraction of hepatic stellate (lto) cells stimulated with vasoactive substances.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
